Acetylmuramyl-Alanyl-Isoglutamine
"Acetylmuramyl-Alanyl-Isoglutamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptidoglycan immunoadjuvant originally isolated from bacterial cell wall fragments; also acts as pyrogen and may cause arthritis; stimulates both humoral and cellular immunity.
| Descriptor ID |
D000119
|
| MeSH Number(s) |
D09.067.550.050 D09.811.522.050 D12.644.233.050
|
| Concept/Terms |
Acetylmuramyl-Alanyl-Isoglutamine- Acetylmuramyl-Alanyl-Isoglutamine
- Muramyl Dipeptide
- Dipeptide, Muramyl
- Acetylmuramyl Alanyl Isoglutamine
- Alanyl Isoglutamine, Acetylmuramyl
- Isoglutamine, Acetylmuramyl Alanyl
Mur-NAc-L-Ala-D-isoGln- Mur-NAc-L-Ala-D-isoGln
- Mur NAc L Ala D isoGln
- N-Acetylmuramyl-L-Alanyl-D-Isoglutamine
- N Acetylmuramyl L Alanyl D Isoglutamine
- N-Acetyl-Muramyl-L-Alanyl-D-Glutamic-alpha-Amide
- N Acetyl Muramyl L Alanyl D Glutamic alpha Amide
|
Below are MeSH descriptors whose meaning is more general than "Acetylmuramyl-Alanyl-Isoglutamine".
Below are MeSH descriptors whose meaning is more specific than "Acetylmuramyl-Alanyl-Isoglutamine".
This graph shows the total number of publications written about "Acetylmuramyl-Alanyl-Isoglutamine" by people in this website by year, and whether "Acetylmuramyl-Alanyl-Isoglutamine" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Acetylmuramyl-Alanyl-Isoglutamine" by people in Profiles.
-
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer. 2009 Nov 15; 115(22):5339-48.
-
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005 Mar 20; 23(9):2004-11.
-
Biologic response modifiers in pediatric cancer. Hematol Oncol Clin North Am. 2001 Aug; 15(4):723-40, ix.
-
ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity. Cancer Immunol Immunother. 1999 Sep; 48(6):312-20.
-
Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine. 1993; 11(9):909-13.
-
Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Biother. 1993; 8(4):307-18.
-
Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives. Cancer Immunol Immunother. 1986; 21(2):93-9.
-
Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes. Cancer Res. 1985 Dec; 45(12 Pt 1):6188-93.
-
Prophylaxis of murine candidiasis via application of liposome-encapsulated amphotericin B and a muramyl dipeptide analog, alone and in combination. Antimicrob Agents Chemother. 1985 Oct; 28(4):511-3.
-
Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine. Clin Exp Metastasis. 1984 Apr-Jun; 2(2):127-37.